Nynomic, a German technology firm, faced a disastrous second quarter in 2025, with revenue plunging 13% to €21.5 million and an operating loss of €1.1 million—a stark contrast to the €2.6 million profit a year prior. Analysts slashed price targets by nearly 30%, citing a 27% collapse in order backlog to €43.4 million due to geopolitical tensions and trade restrictions delaying customer investments. Despite maintaining a "buy" rating, NuWays reduced its target to €24.50, acknowledging severe setbacks. The company’s full-year outlook dimmed, with revenue now projected at €100–105 million (down from €105–110 million) and operating profit expectations halved to €2–4 million.
Restructuring Offers Glimmer of Hope
Nynomic’s cost-cutting initiative, "NyFIT2025," aims to save €5–6 million annually from 2026, but current restructuring costs of €1.5 million and a 5% workforce reduction weigh on results. Management pins hopes on a sequential recovery, particularly in Q4, traditionally its strongest quarter. Analysts note potential for margin gains if demand rebounds, though near-term risks loom large amid weak order visibility.
Ad
MUT Stock: Buy or Sell?! New MUT Analysis from February 7 delivers the answer:
The latest MUT figures speak for themselves: Urgent action needed for MUT investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
MUT: Buy or sell? Read more here...
